Literature DB >> 10378874

Subcutaneous administration of T-epitope sequences of the acetylcholine receptor prevents experimental myasthenia gravis.

P I Karachunski1, N S Ostlie, D K Okita, R Garman, B M Conti-Fine.   

Abstract

Immunization with acetylcholine receptor (AChR) causes experimental myasthenia gravis (EMG). The s.c. administration to C57B1/6 mice of synthetic AChR CD4+ epitopes, before and during AChR immunization, reduced the epitope-specific CD4+ responses and the anti-AChR Ab synthesis, and prevented EMG. The s.c. administration of solubilized AChR had effects similar to those of peptide treatment. Sham-tolerized mice had only Th1 anti-AChR cells, whereas peptide-treated mice had also Th2 cells, and Th2-induced anti-peptide Ab. Established EMG was not affected by s.c. peptide treatment, whereas it worsened after s.c. administration of solubilized AChR.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10378874     DOI: 10.1016/s0165-5728(98)00208-2

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  8 in total

1.  Oral administration of a dual analog of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice.

Authors:  M Paas-Rozner; M Dayan; Y Paas; J P Changeux; I Wirguin; M Sela; E Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-29       Impact factor: 11.205

2.  Oral administration of an immunodominant T-cell epitope downregulates Th1/Th2 cytokines and prevents experimental myasthenia gravis.

Authors:  F Baggi; F Andreetta; E Caspani; M Milani; R Longhi; R Mantegazza; F Cornelio; C Antozzi
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

Review 3.  Vaccines against myasthenia gravis.

Authors:  Sonia Berrih-Aknin; Sara Fuchs; Miriam C Souroujon
Journal:  Expert Opin Biol Ther       Date:  2005-07       Impact factor: 4.388

4.  Mapping myasthenia gravis-associated T cell epitopes on human acetylcholine receptors in HLA transgenic mice.

Authors:  Huan Yang; Elzbieta Goluszko; Chella David; David K Okita; Bianca Conti-Fine; Teh-sheng Chan; Mathilde A Poussin; Premkumar Christadoss
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

Review 5.  Myasthenia gravis: past, present, and future.

Authors:  Bianca M Conti-Fine; Monica Milani; Henry J Kaminski
Journal:  J Clin Invest       Date:  2006-11       Impact factor: 14.808

6.  The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes.

Authors:  M Paas-Rozner; M Sela; E Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

7.  Myasthenia gravis and the tops and bottoms of AChRs: antigenic structure of the MIR and specific immunosuppression of EAMG using AChR cytoplasmic domains.

Authors:  Jon Lindstrom; Jie Luo; Alexander Kuryatov
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

8.  Current and emerging treatments for the management of myasthenia gravis.

Authors:  Sivakumar Sathasivam
Journal:  Ther Clin Risk Manag       Date:  2011-07-22       Impact factor: 2.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.